News & Resources

Erosion of The Supratentorial White Matter Reference for Increased Power in Longitudinal Amyloid PET

The use of the supratentorial white matter as a reference region, alone 1 7 or in composite 3 can facilitate the detection of subtle changes in amyloid plaque burden Investigators often erode or otherwise restrict the sWM labels to reduce the influence of signal “spill in” from grey matter 2 4 8 but the optimal extent…

• Date: 05/08/2024

Appointment of CEO - Bram Goorden

IXICO plc (AIM: IXI), the precision analytics company delivering intelligent insights in neuroscience, is pleased to announce that Bram Goorden will be appointed as Chief Executive Officer of the Company from 19 August 2024.

Advancing Alzheimer's Research: enhancing clinical trial diversity and relevant imaging considerations

• Category: Global Alzheimer's Platform, Alzheimer's Disease, PET Imaging
• Date: 23/05/2024

IXICO to support on Global Alzheimer's Platform Foundation's Bio-Hermes 2 trial

IXICO plc (AIM: IXI), the medical imaging advanced analytics company delivering insights in neuroscience announces that it has signed a contract with the Global Alzheimer's Platform Foundation® ("GAP") to support GAP's planned Bio-Hermes 2 trial. The contract value is worth over £1 million over a 48-month term.

• Date: 15/04/2024

Life Molecular Imaging Collaboration Agreement

15 April 2024, IXICO plc (AIM: IXI), London, UK, the medical imaging advanced analytics company delivering intelligent insights in neuroscience, today provides information on its agreement with Life Molecular Imaging (LMI) for the supply of LMI's Neuraceq® Amyloid PET tracer (Florbetaben-18F) for use in pharma-sponsored clinical trials.

• Category: Alzheimer's Disease, Multiple Sclerosis, MRI, White Matter Imaging, Neuroinflammation
• Date: 03/04/2024

Imeka Collaboration Agreement

3 April 2024, IXICO plc (AIM: IXI), the medical imaging advanced analytics company delivering intelligent insights in neuroscience, announces a collaboration agreement with IMEKA Solutions Inc. ("Imeka") to provide access to Imeka's suite of services for white matter1 imaging deployed in Alzheimer's Disease (AD) and Multiple Sclerosis (MS) clinical trials, amongst other CNS indications.

Multiple Sclerosis – Advancing treatment through imaging biomarkers

Association between regional volume change and clinical change in Huntington’s disease HD-ISS Stage 2 and Stage 3 participants

For HD-ISS Stage 2 and Stage 3 participants, whole-brain volume shows significant association with clinical change for all four clinical variables examined here. For caudate and putamen volume, the association depended on the clinical variable. Our results provide further evidence on the use of volume change as a surrogate endpoint.